has been reprimanded by U.K. regulators for failing to disclose fees and expenses paid to individuals and organizations in Britain amounting to about £7.8-million between 2020 and 2022.
Novo, whose valuation has soared following the success of its diabetes drug Ozempic and weight loss treatment Wegovy, said on Friday that it had made the voluntary admission in 2023 after it found historical payments that had not been disclosed. “We accept the PMCPA’s decision to rule the relevant breaches of the two Codes of Practice which applied during the time frame for this case and agreed that this was the appropriate ruling as part of our voluntary admission.”
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: